BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

Jorge Wagner

Session 2 – Pharma-biotech Partnering & Collaboration

Date:21 July (Wednesday)
Time:  12:20 – 13:50 (GMT+8)

Jorge Wagner

General Manager & Country President 
Novartis (Taiwan) Co., Ltd.

 

Jorge Wagner is a passionate and distinguished commercial leader with over 25 years of multinational experience in the pharmaceutical industry. He has a wide spectrum of capabilities and professional experiences in marketing and general management across different geographic areas and cultures, including Indonesia, Germany, Argentina, Ecuador, and Taiwan, demonstrating leadership and impact on local and regional level. He establishes a strong record of driving commercial excellence and leading cultural transformation while dedicating policy shaping and governmental affairs.
 
Jorge is appointed as Country President at Novartis Taiwan since November, 2020, and relocated from his previous role as Country President of Novartis in Jakarta, Indonesia. He is currently a board member of International Research-Based Pharmaceutical Manufacturers Association (IRPMA), Taiwan, and also serves as a co-chair of pharmaceutical committee in European Chamber of Commerce Taiwan (ECCT) from June, 2021. During his time in Indonesia, he was the Chairman of the Indonesian International Pharmaceutical Companies Association (IPMG) from 2017 to 2020.
 
Prior to Novartis, Jorge worked for more than 20 years at Boehringer Ingelheim, and had various roles worldwide. He received his Industrial Engineer degree from the Instituto Tecnologico Buenos Aires and obtained his post graduated in Marketing from the University of San Andres, Buenos Aires, as well as studied at London Business School.

Speech title & Synopsis

Collaboration between Novartis and Acer on medical Artificial Intelligence - The power of cross-industry partnering

Taiwan has world famous healthcare system, comprehensive healthcare data (especially the NHI) and world leading ICT industry with advanced AI capability. Leveraging the expertise of pharma and technology companies, the collaboration can build a strong smart healthcare ecosystem, to contribute to the enhancement of quality of care, optimization of resource utilization, and also the creation of great economic values for the society.

In this talk, Novartis and ACER will co-present the VeriSee case and share their perspectives how they see the opportunities in the future, and the power of cross-industry partnering.